| Names | |
|---|---|
| Preferred IUPAC name | (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]hexanamide |
| Other names | GnRH agonist LHRH agonist D-Ala6-GnRH Luteinizing hormone-releasing hormone analog Alarelina Alareline |
| Pronunciation | /əˈlær.ə.lɪn/ |
| Identifiers | |
| CAS Number | 79561-22-1 |
| Beilstein Reference | 1632002 |
| ChEBI | CHEBI:8637 |
| ChEMBL | CHEMBL2105957 |
| ChemSpider | 55159 |
| DrugBank | DB13919 |
| ECHA InfoCard | 100.214.336 |
| EC Number | 863035-44-3 |
| Gmelin Reference | 1462224 |
| KEGG | D04626 |
| MeSH | D017367 |
| PubChem CID | 6918297 |
| RTECS number | DJ1KX8NQ0L |
| UNII | J7755B8I5Q |
| UN number | UN number not assigned |
| CompTox Dashboard (EPA) | DTXSID70872796 |
| Properties | |
| Chemical formula | C55H74N16O12 |
| Molar mass | 1167.3 g/mol |
| Appearance | White powder |
| Odor | Odorless |
| Solubility in water | Soluble in water (≥ 1 mg/mL) |
| log P | -4.5 |
| Acidity (pKa) | 10.17 |
| Basicity (pKb) | 8.94 |
| Dipole moment | 3.25 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 306.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | H01CA95 |
| Hazards | |
| Main hazards | May cause skin, eye, and respiratory irritation. |
| GHS labelling | GHS labelling: No hazard pictogram, No signal word, No hazard statement, No precautionary statement |
| Pictograms | GHS06, GHS08 |
| Signal word | No signal word |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P280, P302+P352, P305+P351+P338, P362+P364, P501 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 0, Instability: 0, Special: - |
| PEL (Permissible) | Not established |
| REL (Recommended) | 5-10 µg/kg |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds | Gonadorelin Deslorelin Goserelin Leuprorelin Triptorelin |
| Property | Description & Manufacturer Commentary |
|---|---|
| Product Name | Alarelin |
| IUPAC Name | Typically, Alarelin is referred to as 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-alanyl-L-leucyl-L-arginyl-N-ethylamide in official nomenclature. International suppliers and research users utilize this IUPAC name for regulatory and sourcing documentation. Manufacturers rely on this to differentiate the peptide sequence, especially when identifying structural analogues produced via custom solid-phase synthesis. |
| Chemical Formula | C56H78N16O12 – derived directly from the amino acid sequence. Peptide purity grades impact analytical confirmation of this molecular formula, as non-peptide byproducts and truncated chains can introduce analytical interference if not properly removed during purification. |
| Synonyms & Trade Names | Synonyms include Alarelin Acetate, Gonadorelin (synthetic), [D-Ala6,Pro9-Net]-LH-RH. Laboratory and industrial-grade lots typically reference both synonyms and peptide code numbers for cross-checking regulatory paperwork, particularly when aligning product documentation between synthetic lots and bioassay standards. |
| CAS Number | 79561-22-1 as the primary reference code. This identifier is fundamental for batch traceability down to individual synthesis runs, especially for compliance with local and international registration protocols. |
| HS Code & Customs Classification | For peptide-based pharmaceutical intermediates, the commonly designated HS Code is 2937.19, which covers polypeptides and their derivatives not elsewhere specified. Many jurisdictions require HS assignment based on the final application (research, veterinary, or pharmaceutical), and industrial manufacturers are responsible for providing all supporting synthesis and origin documents to customs officials when clearing peptide lots. Classification should follow national customs code amendments, and misclassification can delay shipments or incur significant penalties at point of entry. |
Alarelin typically appears as a white to off-white solid in lyophilized powder form. A mild characteristic odor sometimes arises during synthesis or formulation but is rarely perceptible in final purified material. The melting point and other physical constants can shift depending on the hydration state and salt form, with small variations observed across different grades and production lots. Observing proper handling during lyophilization and milling prevents powder compaction and agglomeration, which can interfere with downstream solubilization.
Alarelin shows reliable peptide stability under inert, low-moisture storage. Degradation risk increases under heat, exposure to acids, bases, or oxidants, and in the presence of proteases. Stability can vary by batch, especially with impurity profiles and salt content. Both the primary sequence and peptide modifications influence reactivity during conjugation or formulation. Material exhibiting unexpected yellowing or strong odors often signals degradation or contamination.
Production experience indicates water solubility is grade-dependent. Peptide salts dissolve in distilled, buffered, or isotonic waters; intractable aggregates sometimes require gentle heating or mild sonication. Handling high-purity grades demands freshly prepared, sterile solutions. Properly controlling pH and ionic strength in water reduces peptide aggregation and loss to vessels, especially at low concentrations. Poor dissolution or visible particulates point to process residues or unfavorable salt forms.
Analytical specification tables depend on whether intended for research, clinical, or veterinary applications, as purity, identity, and content requirements tighten with usage risk. Lower-grade technical material typically supports animal testing, with human-use and regulated markets imposing stricter impurity controls and documentation. Product is generally released by peptide content, purity (by HPLC), residual solvents, and water content—each determined according to internal SOPs and customer needs.
Typical impurities originate from incomplete synthesis, side-chain protection cleavage, resin-derived contaminants, and solvent residues. Primary unknown or minor peaks on chromatograms prompt root cause investigation in scale-up lots. Batch-to-batch impurity drift often tracks raw material batch changes or minor process parameter deviations. Regulatory submission materials require consistently demonstrated impurity levels within internal or pharmacopeial specifications, validated by qualified reference standards.
Quality assessment relies on a combination of reversed-phase HPLC, LC-MS analysis, amino acid analysis, and water content (KF). Manufacturing departments validate all methods before routine release. The actual test protocol—column selection, gradient, detection mode—is matched to the product grade and customer requirements, with method robustness monitored throughout campaign production. Out-of-spec results demand root-cause analysis and possible purification rework.
Alarelin production employs protected amino acid derivatives and specialized resins selected according to internal supply chain audits and traceability documentation. Manufacturer preference skews to proven, audited vendors with batch consistency data and impurity control certificates. Depending on the grade, strict source validation aligns to global regulatory expectations and limits cross-batch variability.
Solid-phase peptide synthesis serves as the production backbone, using Fmoc- or Boc-based stepwise condensation on resin. Reaction monitoring employs in-process cleavage and test deprotection after each coupling. Process modifications—such as alternative protection strategies or resin types—allow scale, impurity minimization, or special downstream tailoring. Weak coupling steps, resin fouling, or anomalous by-products signal areas for route optimization.
In-process inspection points verify coupling completion, deprotection integrity, and prevent resin over-drying. Chromatography (RP-HPLC, preparative) or membrane separations address crude product clean-up, while precipitation and lyophilization finalize isolation. Each process run receives a unique traceability batch record, enabling tracking from raw material input to final product. Any deviation triggers enhanced testing and potential batch quarantine.
Quality release hinges on meeting analytical and process acceptance specifications set jointly by quality, production, and regulatory teams. Material is only released after evaluating identity, purity, peptide content, solvent residues, and water. Internal standards and spikes control method drift or failures. Batch release certificates build on a documented analytical, process, and deviation record for each lot, backed by retained reference samples.
Alarelin supports acylation, conjugation, and PEGylation under controlled lab conditions, which extend its application or pharmacokinetic profile. Most modification strategies utilize the N-terminal amino or C-terminal functional groups for targeted downstream chemical processing. Reaction efficiency links directly to starting peptide purity and sequence accessibility.
Manufacturing experience shows selective modifications often employ mild, aqueous or polar organic solvent systems, controlled temperature, and stoichiometric or catalytic reagents based on the modification type. Reaction optimization prevents over-modification or sequence degradation, especially in scale-up or continuous operations.
Depending on customer or internal R&D direction, downstream derivatives include labeled versions for bioassays, as well as conjugates for slow release, targeting, or altered bioactivity. Synthesis of complex derivatives demands strict raw material screening and careful in-process monitoring for functional integrity and side-product suppression.
Recommended storage involves sealed, low-humidity, inert-atmosphere packaging in the dark at refrigerated or sub-zero temperatures when possible, tailored to product grade and end-use certification. Oxidation-sensitive forms and formulated products call for nitrogen purged vials and light-opaque containers. Fluctuating environmental conditions or improper resealing contribute to hydrolysis, aggregation, or loss of biological activity.
Lyophilized alarelin maintains stability in HDPE, glass, or specialty polymer vessels, with validation checks for extractables or leachables for each container system. Regulatory or customer specifications may dictate container grade and closure type based on transportation, dispensing, or end-use application.
Practical shelf life depends on storage stringency, with optimal conditions preserving peptide potency and solubility. Early signs of instability include off-white discoloration, unusually slow dissolution, or insolubility, typically signaling hydrolytic or oxidative degradation. Routine stability testing provides end-of-life data according to manufacturing and customer guidelines.
Hazard classification depends on regulatory submission and material review; for most peptide products, risk level aligns with structural class and intended application. Peptides for research and veterinary use differ in classification versus those for human clinical use. Classification is subject to change with new toxicology information or regulatory updates.
Operators should avoid inhalation, skin, and eye contact with powders and solutions, minimizing dust formation during handling and weighing. Standard protective gear—gloves, goggles, lab coats—reduces cross-contamination and personal exposure. Good laboratory hygiene limits unintended exposure, supported by dedicated transfer and weighing setups.
Toxicological profiles account for species, administration route, and intended grade. Acute toxicity is low for most synthetic peptides in laboratory handling, but specific system effects depend on dose, purity, and physiological context. Official regulatory submissions use validated study data, but additional caution applies to high-dose, chronic, or inhalation routes outside standard animal test settings.
No established occupational exposure limits exist for alarelin peptide as a class. Inhalation exposure is minimized by powder handling controls and local exhaust ventilation in production suites. All personnel receive training in material-specific handling and spill containment protocols. Any sign of sensitization or unexpected effect classifies as an incident, triggering root-cause review and possible process adaptation.
Annual output for Alarelin remains dictated by both the complexity of solid-phase peptide synthesis and the constraint on GMP-grade raw materials. Batch size in the dedicated peptide line fluctuates according to demand forecasts and pre-approved production slots. In years where major animal health clients in Europe and Asia ramp up procurement, production schedules shift to prioritize large-lot, bulk synthesis. Lead time varies between 2-6 weeks for standard grades, and custom solutions or higher-purity lots require additional validation and extended cycle times. Output is calibrated tightly: overproduction risks waste due to shelf-life limitations; underproduction means long allocation queues and risk of customer switching.
MOQ for most markets sets at batch-based minimums, with custom grades or packaging demanding higher thresholds. New projects or novel formulation grades drive up MOQ as more in-process checks are built into the timeline. Lead time extends for orders requiring documentation packs for regulatory review or additional finished-product testing, especially where pharmaceutical audits or veterinary submission is necessary.
Choice of final packaging derives from end-user segment and route of administration. Primary packaging follows secondary containment in accredited cleanroom conditions, and bulk packaging for larger industrial contracts typically uses multi-layered, low-permeability liners with tamper-evident seals. For preclinical or pilot customers, smaller aliquots are handled using single-dose containers or vials, each batch traceable and labeled per dispatch and jurisdictional regulation.
Shipping options depend on regional stability and client supply chain reliability. Terms frequently use EXW or FCA for overseas contracts. Temperature-controlled logistics require validated shippers, particularly when regulatory agencies enforce cold-chain or specific storage conditions. Payment structures rely on credit approval, with larger clients negotiating longer payment terms post-verification, while new clients adhere to advance payment or LC-backed release.
Raw material cost for Alarelin remains vulnerable to market dynamics for protected amino acid derivatives, resins, and specialty reagents. Price shocks commonly arise from geopolitical tension, plant shutdowns within the upstream fluorochemical or protection group sectors, and regulatory shifts in environmental controls, which alter access to precursor chemicals. Increased regulatory scrutiny over hazardous process intermediates can introduce compliance surcharges or reroute procurement to higher-priced, audited sources. Yield variations from batch to batch tie closely to challenging peptide couplings and frequent purification cycles required by stricter impurity profiles, with lower-yield lots increasing cost per kilogram for the entire plant.
Significant price spread follows differences in grade—standard industrial, research, pharmaceutical—with GMP batches commanding the highest premium due to higher labor costs, longer cycle times, and additional analytical release burden. High-purity demands increase cost through extended HPLC purification and larger quantity of consumables. Certification for packaging (such as ISO or local veterinary certs) also influences pricing as compliant factories incur higher validation costs and batch record overhead. Certain customers, like those in regulated pharma or animal health, sustain more rigorous release testing and documentation, further driving unit price.
Global demand for Alarelin is closely tied to reproductive management protocols in veterinary and aquaculture industries, creating periodic surges coinciding with agricultural cycles and regulatory approvals in target economies. Major supply nodes reside in East Asia and Europe, with US and Indian producers entering the space selectively due to differing regulatory thresholds and cost structures.
The US and EU markets maintain high compliance requirements, often demanding full GMP traceability and limiting participation to facilities with prior audit success. Pricing here stands less volatile but higher than in open-markets like India or China, where procurement cost can swing on the back of currency shifts or raw material bans. Japanese buyers prioritize long-term reliability and typically sign multi-year agreements, reducing their exposure to spot-market volatility. In China, regional environmental controls frequently disrupt both supply and pricing stability, as urban-area manufacturers face unplanned shutdowns with little advance warning and must source raw materials irregularly.
Looking toward 2026, input costs for protected amino acids and specialty synthesis reagents remain a dominant factor in the overall price curve. Forward contracts tied to agricultural planning cycles could see upward pressure as regulatory constraints in EU and East Asia restrict the number of accredited supply sources. Quality certification costs and ongoing investments in contamination control and impurity profiling are set to drive a gradual year-on-year increase, particularly for GMP and high-purity grades. Conversely, process efficiency projects and vertically integrated producers may stabilize baseline prices in regions where compliance infrastructure is mature. Geopolitical risk and logistics reconfiguration could introduce further unpredictability, influenced by trade policy and cross-border shipping reliability.
Internal price modeling draws from plant cost sheets, subcontractor quotations for raw materials, third-party regulatory bulletins, and real-time procurement records. Market intelligence supplements this with published customs data, regulatory policy notices, and comparative pricing observed in actionable supply contracts. Process R&D feedback refines cost-impact forecasts for efficiency upgrades and yield improvement initiatives.
Recent years saw end-client industries prioritize traceability and batch-release transparency, due to safety audits and import scrutiny. Sudden policy changes or recalls push stringent trace-level impurity controls onto all approved batches, accelerating turnover of quality control protocols and cross-plant technology transfers to secure uninterrupted supply.
Ongoing tightening from EMA and FDA on peptide impurity profiles and process safety documentation forces recalibration of batch records and in-process controls, raising the compliance threshold for exporters. Regulatory amendments in China and India increasingly require production site environmental audits, which can cause abrupt temporary halts in manufacturing while remediation plans are executed.
To cushion production impact, manufacturers are proactively diversifying supply sources for high-risk precursors and recalibrating process flows to tolerate raw material substitutions without significant batch variability. Capacity balancing between different facilities and enhancing cold-chain logistics infrastructure reflect operational responses to shipping delays and regulatory bottlenecks. Corporate quality teams expand batch-release validation pipelines, ensuring rapid compliance with evolving market entry requirements and minimizing recall or approval delays.
Alarelin serves as a synthetic decapeptide GnRH agonist. In practice, manufacturers supply distinct grades depending on application areas, with key demand from pharmaceutical research, life sciences, assisted reproduction, and aquatic breeding. The technical department routinely receives project requests spanning controlled ovulation induction in livestock, model compound in mechanistic studies, and reagent-grade use in academic research. For industrial users, matching product consistency and analytical verification to protocols drives grade definition. R&D and reference applications require higher scrutiny versus mass formulations or basic research.
| Application | Recommended Grade | Evaluation Focus |
|---|---|---|
| Biomedical Research | Research Grade | Identity, amino acid sequence confirmation, HPLC area % |
| Pharmaceutical Development | GMP/Pharma Grade | Impurity profile, residual solvents, batch traceability, compliance with regulatory guidelines |
| Aquaculture Reproduction | Technical Grade | Content verification, absence of toxic residues Water solubility assessment |
Research teams often center on sequence integrity and analytic purity, confirmed by HPLC/LCMS. For pharmaceutical projects, qualified grades demand additional testing for internal and external standards, often involving stability under defined storage, residual solvent thresholds, and heavy metals screening. Animal reproduction protocols may tolerate a broader impurity profile but require batch-to-batch consistency. In export projects, local regulatory checks (pharmacopoeia alignment, REACH/US FDA/EU compliance) frequently add region-specific testing parameters.
Clarify whether the intended use is for in vitro assay, pilot animal trial, or as part of a regulated pharmaceutical intermediate program. Application type determines analytical burden and documentation.
Check jurisdiction for end-use, including requirements established by pharmacopeias, animal health authorities, or ethics panels. For regulated markets or clinical research, suppliers route requests to audits covering GMP or ISO standards. For internal R&D or academic uses, streamlined grades reduce lead times.
Select grades supporting minimum acceptable impurity content. Purity definition always depends on detection methodology (HPLC, UPLC, MS) and project risk tolerance. Residual solvent, heavy metal, and degradation product tests will be grade-dependent, with more demanding protocols for pharma-grade lots.
Volume planning remains critical. Production runs for large-scale field trials or long-term projects benefit from cost-exposed, technical specifications, whereas early-stage research projects typically accept smaller-scale, higher-purity lots. Differences in batch size management affect price per milligram and may limit which grades deliver consistent supply.
Manufacturers encourage requesting a lot-specific COA with analytical data and, where feasible, a pre-shipment sample. This practice allows technical teams to match the lot against application needs, including methods for solubility, storage, impurity retention, and test panel compatibility. Internal QC evaluates validation feedback before committing to production volume or long-term supply contracts.
From the start of Alarelin production, raw materials are reviewed against current pharmaceutical and industrial control lists. The manufacturing process operates within a documented Quality Management System, as recognized by external auditing and relevant certifications at site level. These systems undergo regular review and challenge, involving cross-checks of production histories and deviation management. The specifics of ISO certification, GMP site status, and audit traceability depend on the end-use segment and export destination. Customers can request audit summaries or site qualification packages to verify the facility's compliance status.
Certification of analysis batches includes detailed impurity profiling, identity confirmation using established analytical protocols, and chromatographic purity assessment for each grade. Certifications for Alarelin are tied to route of synthesis and downstream process control, as these influence impurity pattern and batch-to-batch consistency. End-use segments such as biomedical, research, or regulated markets may require additional documentation or local certificates. Reference standards and testing parameters follow internal methods unless otherwise specified by the purchaser.
Each lot is accompanied by a release report, documenting all analytical test outcomes as set by order specification and internal acceptance limits. These include purity profile, related substance levels, water content (if relevant), and process analytical technology records. Upon request, further documentation such as batch manufacturing record summaries, traceability of starting materials, and route-specific impurity justifications can be arranged. Documentation depth varies if the product is destined for regulated market supply, custom synthesis, or general research purposes.
In the plant, Alarelin scheduling is managed alongside other peptide syntheses, with core lines reserved for recurring contract volumes and a separate allocation for pilot or development batches. Capacity expansion planning takes into account predictable demand surges and supply continuity during process upgrades or maintenance windows. Cooperation modes can include fixed annual contracts, on-demand purchases, or rolling forecasts—negotiated according to the customer’s actual pickup rate, regulatory obligations, and buffer stock planning.
Base production runs leverage a multi-parallel synthesizer setup, reducing cross-contamination risk and minimizing changeover downtime. Output per batch and lot release size are set in consultation with downstream users, accounting for assay variations and specification drift over transport or intermediate storage. For longer supply chains or special purity classes, tighter lot reservation and staggered shipment schedules can be developed to absorb potential transportation or import variances.
Customers intending to qualify Alarelin for a new process may request pilot-scale or laboratory evaluation samples via a documented application route. The application requests precise intended use, target specification, and any local regulatory reporting requirements. Sampling is pulled from representative manufacturing campaigns, with full traceability and supporting documentation. Feedback from sample trials helps drive modifications in scale-up or final release criteria to address user-specific processing or formulation challenges.
Business engagement for Alarelin can proceed as a frame supply agreement, progressive scale-up project, or discrete research supply—based on customer production rhythm and risk management strategy. Quantity, release frequency, and logistical alignment are matched to real-time feedback and actual consumption. Customers with planned process scale-up or multi-center trials often use milestone-based drawdown or rolling forecasts, allowing both supplier and buyer to balance inventory risk, shelf life, and in-use performance. This adaptability is supported by real-time production tracking and direct communication between production, logistics, and end-user technical teams.
Recent shifts in reproductive medicine and aquaculture practices have intensified interest in synthetic GnRH analogs like Alarelin. In fermentation-based or solid-phase peptide synthesis (SPPS) routes, consistent demand for high-purity intermediates drives nonstop development of process refinement, impurity risk management, and scale-up reproducibility. Researchers target improved selectivity in peptide bond formation, minimizing racemization risks, and lowering total organic impurity load, which directly impacts batch release requirements. Development teams monitor solid-phase resin choice, cleavage cocktail composition, and side-chain protection strategies because incomplete deprotection or resin adhesion can complicate purification and final folding, especially for injectable-grade product.
Alarelin’s application extends from controlled ovulation induction in veterinary medicine to research protocols in laboratory species management. Investigations increasingly focus on modulating release kinetics and stability by designing depot formulations, such as microspheres and sustained-release implants. These delivery systems depend heavily on manufacturing control at each stage, from initial peptide synthesis through peptide encapsulation and sterilization. Specialty grades with defined particulate requirements and bacterial endotoxin levels are strictly separated from general-use technical grades.
Main production challenges include the removal of process-related impurities such as truncated sequences, deletion peptides, and residual solvents. Technical breakthroughs have come from integrating multi-dimensional analytical controls (UPLC, LC-MS) into routine production, which allows immediate correction of synthesis deviation or crude peptide quality. New solvent recycling strategies and greener cleavage reagents are being evaluated to address both cost and environmental pressure from spent process chemicals. Process adaptation for large-scale batches introduces issues with mixing, temperature control, and byproduct isolation; batch-to-batch consistency relies on setting process windows governed by statistical process control, especially in multi-sequence peptide products where each residue’s coupling yield must be proven within defined control limits.
The continued adoption of hormone-based protocols in vertebrate species, alongside regulatory support for animal welfare-compliant breeding methods, signals resilient demand growth for Alarelin of defined purity grades. Supply planning focuses on managing the seasonal and regulatory-driven fluctuations in demand from both research and commercial sectors, with customer pre-order programs informing raw material procurement schedules. Procurement teams closely follow regional regulatory announcements about hormone product eligibility, as market entry for API or formulated product can change based on shifting import/export controls.
Anticipated process improvements include increased automation in peptide assembly and inline analytics to detect synthesis drift before batch commitment. Modification of resin recycling protocols and exploration of process intensification—such as continuous-flow chemistry—are under internal review to shorten cycle times and improve material efficiency. Process analytical technology (PAT) tools for real-time monitoring of Fmoc removal, coupling completeness, and solvent purity contribute directly to lowering lot-to-lot variability.
Sustainability strategies prioritize minimizing hazardous reagent usage during cleavage and purification, and maximizing the recovery of organic solvents. Solvent reduction and safer alternatives for deprotection and final precipitation (such as ethanol-based quenching in place of acetonitrile or dichloromethane) are being evaluated. Waste stream treatment design meets both regulatory and company-specific environmental performance targets, especially for mother liquors and mother liquors containing residual peptide sequences and scavenger acids. Selection of raw materials increasingly weighs supplier sustainability certifications and traceability, linking quality management with responsible sourcing.
Technical support teams maintain direct involvement with application engineers and laboratory staff at customer sites to resolve formulation, reconstitution, and handling challenges. Product documentation covers: typical solubility in standard diluents, key incompatibilities, and stabilization strategies for application-specific formulations. Support is tailored to grade and target application; veterinary and research users receive different process guidance, especially concerning filtration, sterilization, and storage requirements. Troubleshooting protocols are available for precipitation or aggregation observed during solution preparation.
Customers deploying Alarelin in novel dosage forms or controlled release systems draw on our analytical laboratory capabilities for in-use stability and compatibility testing. Product specialists evaluate lysate or degradation profile compared to freshly reconstituted material, helping clients adjust excipient ratios and device design. OEM and contract formulation projects receive sample lots produced under representative process controls for ramp-up trials, and formulation feedback guides process fine-tuning. Application development is coordinated with regulatory specialists to ensure ongoing compliance.
Each shipped lot is supported by batch release documentation tracing analytical results and key process parameters, with supplementary data available on request for client-defined quality attributes. In-process control records document impurity profiles, moisture levels, and residual solvent status according to grade. If customer QC flags out-of-trend results in their application, investigation routinely draws on retained reference samples and process monitoring records to identify root cause, whether storage, transport, or in-use reconstitution contributed. Replacement and recall protocols operate under strict internal criteria, with commitment to continuous improvement and transparent communication on findings. Ongoing batch monitoring supports both immediate customer needs and long-term product lifecycle management.
Our facility specializes in the direct synthesis of Alarelin, a decapeptide widely used for research and industrial projects in reproductive regulation and veterinary fields. Each batch originates from our in-house process development teams and is validated throughout all critical stages, from raw material verification to final peptide release. This approach eliminates the variability found in outsourced or aggregated supply chains, offering industrial buyers clarity on production standards and control over the entire process.
Alarelin finds primary use among pharmaceutical manufacturers developing hormone-related therapies, as well as animal health product formulators addressing assisted reproduction in aquaculture and livestock. R&D teams in these sectors use our material for both pilot-scale trials and full-scale production support. The predictable quality of our Alarelin supports consistent downstream formulation and bioassay results, aligning with established protocols for both investigational and commercial product pipelines.
Control over synthesis and purification defines our core operational model. Each Alarelin batch undergoes routine HPLC and mass spectrometry confirmation to ensure sequence fidelity and purity within strict tolerances. Our production environment complies with GMP standards. In-process sampling, batch traceability, and documentation support audit requirements for regulated markets. This transparency in documentation allows procurement and quality teams at client sites to streamline compliance checks and integrate our material into highly controlled production settings.
We offer Alarelin in sealed containers suitable for bulk transport, isolating the material from moisture and environmental factors during transit. Shipments utilize packaging that maintains integrity under demanding logistics conditions. Custom lot formats support integration into automated dosing and blending systems at customer production sites. Our logistics team manages both regional and international shipments, aligning with project timelines and just-in-time inventory approaches across client plants.
Our technical specialists offer direct consultation for process engineers and R&D staff evaluating Alarelin integration into manufacturing protocols. Whether questions arise on reconstitution, process compatibility, or analytical validation, our team draws on years of formulation experience to address the technical aspects of peptide use in industrial settings. By working closely with end users’ technical staff, we ensure that our material meets both application benchmarks and regulatory project needs—reducing delays in scale-up and troubleshooting.
With direct access to manufacturing and batch records, clients obtain a transparent, predictable supply of Alarelin without margin stacking or uncertainty linked to intermediary sourcing. Regular supply contracts with production scheduling flexibility allow buyers to reduce inventory holding costs. The integration of our documentation and supply practices into client quality management systems supports risk mitigation and audit readiness for regulated production environments. By managing each stage internally, we give industrial buyers reliability on cost, batch repeatability, and logistical performance over extended partnerships.
We have spent years refining synthesis and quality control processes for Alarelin, a peptide analog with applications in veterinary and reproductive biology fields. The stability of this product begins at the raw material selection stage. Each amino acid batch we purchase undergoes strict verification before peptide assembly proceeds. Solid-phase synthesis and precise cleavage chemistry follow, allowing us to deliver reliable bulk or vialed material. Throughout, the preservation of bioactivity remains our focus. Even traces of moisture or elevated temperature can prompt peptide hydrolysis or oxidation, leading to reduced biological response at the end-user level.
During development, our technical team tracks how various temperatures affect Alarelin’s integrity over time. We store purified, lyophilized peptide below -20°C immediately after packaging. From our analytical testing, Alarelin keeps its bioactivity for years at this temperature, provided the vial remains sealed and dry. Standard packaging includes inert gas purging and robust sealing, which shields the peptide from oxygen and environmental changes during transit and storage.
If clients request a ready-to-use aqueous solution, we recommend cold-chain management throughout distribution. Dissolved peptide maintains its biological structure at 2-8°C for shorter periods, usually under two weeks. Our stability studies confirm that light, air, and warmth accelerate peptide breakdown. Repeated freeze-thaw cycles introduce micro-cracking and denaturation. We always advise dividing bulk reconstituted material into single-use aliquots—this reduces handling, ensuring consistent potency from opening to administration.
Many of our clients operate in regions with inconsistent electric power or temperature control. Logistics or customs delays add further complexity. To address these realities, we rigorously validate each production lot using HPLC and mass spectrometry before shipping and monitor shipping conditions to align with international temperature-sensitive cargo guidelines. If temperature excursions occur, our technical team can provide fact-based guidance on product suitability.
Peptide drugs like Alarelin have no shortcuts—the molecule is sensitive by nature. We invest heavily in freeze-drying technology and automation to eliminate variability. Strict protocols reduce risk at every step. We use high-barrier primary and secondary packaging, and we provide training for storage and reconstitution practices. Every shipment includes a detailed product insert outlining handling to maximize active life, as well as batch-specific analytical data for verification.
With peptide therapeutics, detail determines reliability. We encourage research teams, clinics, and manufacturing partners to follow evidence-based storage, use aliquoting strategies, and avoid unnecessary manipulation. We see the result in consistent assay performance, satisfied clients, and the progress of science using stable, robust Alarelin material as manufactured in our facilities.
Procuring bulk Alarelin directly from the manufacturer means you work with the actual production team, not intermediaries. Our experience in peptide synthesis shapes how we set minimum order quantities and production lead times. Chemical manufacturing never runs on guesswork; consistent process control and quality batch management require clear planning from both sides.
MOQ for Alarelin reflects process efficiency and the realities of scaling. Peptide batches involve complex synthesis, purification, and final lyophilization. Laboratory-scale reactions rarely translate to commercial reliability on small runs, so a MOQ is necessary to ensure analytical control, stability validation, and reproducible purity. For most peptide products, MOQ aligns with the lowest scale that maintains stable, consistent quality and economically balanced logistics. Peptides demand investment in precursor chemicals, custom synthesis, filtration, and extended analytical testing. A plant-sized MOQ reflects investment in cGMP-grade or industrial peptide production, rather than off-the-shelf supplies.
For Alarelin, MOQ typically starts at a few hundred grams, based on industrial reactor volumes and cost of operations. Each step—solid-phase synthesis, cleavage, purification—requires staff time and validated equipment. Large clients working on veterinary pharmaceuticals or research formulations recognize that economies of scale benefit both the manufacturer and the buyer, as unit cost drops with larger batches.
Lead time for Alarelin is driven first by raw material procurement, followed by synthesis and batch release testing. Selling chemicals from stock rarely suits peptide buyers, due to the stringent demand for fresh, stable, traceable batches. Starting from raw materials, our team outlines a timeline that includes order confirmation, scheduling, synthesis, purification, lyophilization, and extensive analytical review—HPLC, mass spectrometry, purity, and identity assured for every shipment.
Raw material supply can influence timelines, but real time comes from multi-stage peptide manufacturing. Regular runs for popular peptides offer faster delivery, while uncommon custom modifications or new syntheses call for longer planning. Most bulk Alarelin orders run on a 4–8 week lead time, not due to idle waiting, but because each batch passes through hands-on chemical manipulation, then a thorough quality review.
Clients benefit when they communicate technical and timeline needs clearly from the outset. Our technical team reviews each order’s purity, packing, and analytical documentation requests. Fast-track options exist when capacity allows, but chemical synthesis rewards precision over speed chasing. Bulk buyers often want batch reservation and projected production slots; our team logs these requests in the main schedule and keeps all communications direct and up to date.
Bulk procurement means more than transaction processing—it means aligning production capability, raw material logistics, and ongoing process reliability. As a direct manufacturer, we aim to bridge lab chemistry with full-scale supply through real-world expertise. Ordering Alarelin in bulk always starts with clear MOQ and lead time realities, supported by transparent schedules, reliable technical data, and an open channel to our production floor.
We manufacture Alarelin as a synthetic peptide used primarily for research and veterinary applications. Our team manages every stage from raw peptide synthesis to packaging, which means we monitor compliance from the first batch to the final shipment. Exporting regulated peptides like Alarelin brings its own set of regulatory considerations, shaped by national and international controls. As a group deeply involved in global trade, we have encountered a range of import and export requirements that both new and established clients need to navigate.
Many regions classify synthetic peptides under specialized customs categories. Customs regulators might ask for detailed paperwork on origin, purity, usage intention, and final destination, even if the peptide does not qualify as a controlled substance or scheduled pharmaceutical. In our practice, shipments to North America, Europe, and East Asia consistently trigger documentation reviews at ports of entry. We prepare comprehensive shipping documents, including commercial invoices that accurately describe the contents and purpose of Alarelin, along with Certificates of Analysis from our QC department.
Research-only status does not exempt a shipment from local control. Customs authorities rely on information we provide to determine the correct tariff and safety tracking. Our export professionals annotate every document with full product names and harmonized system codes, not generic item descriptions, so authorities can quickly identify the material and understand the intended use. Failing to account for the proper name or use case can invite shipment delays or even refusal. Over the years, we have seen a straightforward, transparent documentation trail speed up clearance. Our regulatory team keeps up with changes in customs code assignments to avoid inaccurate classification.
Some jurisdictions classify Alarelin and similar peptides under specific import or export control frameworks due to their biological effects. Medical, veterinary, and research peptides sometimes come under local regulatory oversight, especially if they are used in animal breeding or reproductive work. In such cases, authorities usually require import permits or pre-clearance from health, agriculture, or drug enforcement agencies. To ensure our products arrive without holdups, we always verify ahead of time which agencies need to review the shipment. This process can include securing permits that specify product condition and end-user information or aligning with end-use declarations.
Our technical staff prepares detailed dossiers to support customer permit applications when a country requests scientific or toxicology data. We provide original documentation direct from our manufacturing lines, including synthetic route, purity profile, and analytical data. In some cases, we work directly with regulatory consultants or local legal teams to interpret unclear statutes and obtain agency opinions before shipment.
Our experience has taught us that preparation before shipment minimizes business risk and supports uninterrupted research. We actively monitor regulatory updates affecting research peptides, including updates to customs codes or additional licensing in sensitive sectors. Maintaining robust, transparent product documentation helps both our business and our clients avoid compliance setbacks. For any new territory, we run a regulatory check and review historical cases before confirming a shipment. By engaging in regular dialogue with inspection authorities and staying rigorous in our documentation, we keep Alarelin and other peptides moving safely and efficiently across national borders.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
